X-Mont-LC Syrup is a combination pharmaceutical formulation containing Levocetirizine 2.5 mg and Montelukast 4 mg per dose, designed for the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 histamine receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor CysLT1, reducing bronchoconstriction, inflammation, and edema in the airways, making it effective in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive control of allergic manifestations by targeting multiple inflammatory pathways. X-Mont-LC Syrup is indicated for pediatric and adult patients requiring combined antihistaminic and leukotriene receptor antagonist therapy, particularly in cases where monotherapy is insufficient. It is generally well tolerated, with adverse effects including headache, gastrointestinal disturbances, and fatigue being infrequent and mild. Administration should follow physician guidance, considering contraindications such as hypersensitivity to components. This combination offers an effective therapeutic option for improving quality of life in patients with allergic respiratory disorders.